MindMed Announces Election of All Six Company Nominees at Annual Meeting
21 Junho 2023 - 1:08PM
Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the
“Company” or “MindMed”), today announced that, based upon a
preliminary vote assessment, shareholders have elected all six of
the Company’s nominees – CEO Robert Barrow, Dr. Suzanne Bruhn, Dr.
Roger Crystal, David Gryska, Andreas Krebs and Carol A. Vallone –
to the Board of Directors (the “Board”) at the Annual Meeting of
Shareholders (the "Meeting") held today.
Robert Barrow, Chief Executive Officer and Director of MindMed,
stated: “We would like to sincerely thank our shareholders for
their support and engagement throughout this process. We would also
like to thank both independent proxy advisory firms – Institutional
Shareholder Services (ISS) and Glass, Lewis & Co. – for their
recommendations, which validated our strategy and the quality of
our directors. The entire Board is fully committed to the Company’s
success as we navigate this pivotal period, with two key clinical
readouts expected later this year. We are glad to put this proxy
contest behind us and fully focus on bringing our transformative
therapies to market in order to help patients in need and deliver
value for all shareholders.”
The Company notes that quorum was present at the Meeting and
that the number of shares represented at the Meeting exceeded 40%
of the Company’s outstanding shares entitled to vote.
Final results will be filed on a Form 8-K with the U.S.
Securities and Exchange Commission and will be filed with the
Canadian securities regulatory authorities.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the symbol MMED.
Cautionary Notes and Forward-Looking Statements
Certain statements in this press release related to the Company
constitute “forward-looking information” within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “will”, “may”, “should”, “could”,
“intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”,
“potential” or “continue”, or the negative thereof or similar
variations. Undue reliance should not be placed on forward-looking
information, which are inherently uncertain, are based on estimates
and assumptions, and are subject to known and unknown risks and
uncertainties (both general and specific) that contribute to the
possibility that the future events or circumstances contemplated by
the forward-looking statements will not occur. There can be no
assurance that the plans, intentions or expectations upon which
forward-looking statements are based will in fact be realized.
Forward-looking information in this press release includes, but is
not limited to, statements regarding the preliminary results of the
Meeting, the Company’s business plans and objectives; the ability
of MindMed to achieve success consistent with management’s
expectations; and the Company’s ability to meet the milestones set
forth herein.
Forward-looking information is based on the opinions and
estimates of management of the Company at the date the statements
are made, as well as a number of assumptions made by, and
information currently available to, the Company concerning, among
other things, the preliminary results of the Meeting, the Company’s
business plans and objectives; the ability of MindMed to achieve
success consistent with management’s expectations; and the
Company’s ability to meet the milestones set forth herein. Although
management of the Company considers these assumptions to be
reasonable based on information currently available to it, they may
prove to be incorrect.
There are numerous risks and uncertainties that could cause
actual results and the Company’s plans and objectives to differ
materially from those expressed in the forward-looking information,
including the preliminary results of the Meeting, the Company’s
business plans and objectives; the ability of MindMed to achieve
success consistent with management’s expectations; and the
Company’s ability to meet the milestones set forth herein; as well
as those risk factors discussed or referred to herein and the risks
described in the Company’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2022 and the Company’s Quarterly
Report on Form 10-Q for the fiscal quarter ended March 31, 2023
under headings such as “Special Note Regarding Forward-Looking
Statements,” and “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” and
other filings and furnishings made by the Company with the
securities regulatory authorities in all provinces and territories
of Canada which are available under the Company’s profile on SEDAR
at www.sedar.com and with the U.S. Securities and Exchange
Commission (“SEC”) on EDGAR at www.sec.gov. Except as required by
law, the Company undertakes no duty or obligation to update any
forward-looking statements contained in this press release as a
result of new information, future events, changes in expectations
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230621389945/en/
For Media: media@mindmed.co OR Longacre Square Partners Dan
Zacchei / Miller Winston mindmed@longacresquare.com
For Investors: ir@mindmed.co OR Morrow Sodali Michael Verrechia
/ Eric Kamback MNMD@investor.morrowsodali.com
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024